The conversation revolved around three themes: non-invasive tests as presented at the morning LITMUS session; two promising but incomplete drug trials for a new class of agents and a possible therapy for controlled cirrhotics, and the opportunities and challenges presented by digital meetings (with kudos to EASL for all the platform elements they strengthened from 2020.
TOPICS: AASLD, Akero Therapeutics, aldafermin, cirrhosis, EASL, EchoSens, efruxifermin, ELF, Fatty Liver, FGF-21, FIB-4, FibroScan, Fibrosis Level 3, Fibrosis Level 4, Gilead Sciences, Global Liver Institute, inventiva, lanifibranor, MRI-PDFF, NAFLD, NASH, Nordic Biosciences, Patient Advocacy, Phase3, population screening, Semaglutide, social policy, North Sea Therapeutics, icosabutate, ICONA trial, FAST test, MRE, food insecurity, Pro-C3
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast
